MarketPulse

Rybrevant Faspro

2 articles
BenzingaBenzinga··Vandana Singh

J&J Receives FDA Breakthrough Designation for Rybrevant Faspro in HPV-Negative Head and Neck Cancer

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.
JNJMRKSNYTAKICLRclinical trialimmunotherapy
BenzingaBenzinga··Vandana Singh

J&J Wins FDA Clearance for Accelerated Monthly Dosing of Lung Cancer Therapy

J&J's lung cancer therapy Rybrevant Faspro gains FDA approval for accelerated monthly dosing, maintaining efficacy while improving patient convenience and reducing treatment burden.
JNJFDA approvalRybrevant Faspro